T. Rowe Price Associates
WHWK

T. Rowe Price Associates’s Whitehawk Therapeutics WHWK Stock Holding History

T. Rowe Price Associates’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,692
Closed -$26K – 3048
2024
Q1 		$26K Hold
10,692
– – ﹤0.01% 2923
2023
Q4 		$22K Sell
10,692
-200,000
-95% -$839K ﹤0.01% 2870
2023
Q3 		$1.02M Sell
210,692
-17,705
-8% -$103K ﹤0.01% 1787
2023
Q2 		$1.56M Sell
228,397
-9,332
-4% -$72.5K ﹤0.01% 1579
2023
Q1 		$1.72M Sell
237,729
-7,514
-3% -$80.3K ﹤0.01% 1515
2022
Q4 		$3.15M Sell
245,243
-6,036
-2% -$78.8K ﹤0.01% 1300
2022
Q3 		$3.55M Buy
251,279
+4,041
+2% +$53.1K ﹤0.01% 1268
2022
Q2 		$3.05M Sell
247,238
-188,713
-43% -$2.8M ﹤0.01% 1503
2022
Q1 		$7.4M Sell
435,951
-72,941
-14% -$1.4M ﹤0.01% 1412
2021
Q4 		$12.3M Buy
508,892
+43,293
+9% +$1.09M ﹤0.01% 1378
2021
Q3 		$13M Buy
465,599
+448,686
+2,653% +$13.7M ﹤0.01% 1390
2021
Q2 		$429K Hold
16,913
– – ﹤0.01% 2456
2021
Q1 		$327K Buy
+16,913
New +$389K ﹤0.01% 2533

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates's WHWK Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Whitehawk Therapeutics (WHWK) in Q2 2024, closing a stake of 10,692 shares — an estimated $26K sold.

T. Rowe Price Associates first reported a position in WHWK in Q1 2021 and held it in 13 quarters. The position peaked at $13M in Q3 2021. 65 funds tracked by Wall St. Rank hold WHWK as of Q2 2024.

  • T. Rowe Price Associates reported no remaining Whitehawk Therapeutics position as of Q2 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 10,692 Whitehawk Therapeutics shares in Q2 2024, an estimated $26K.
  • T. Rowe Price Associates first reported a position in Whitehawk Therapeutics in Q1 2021 and held it in 13 quarters.
  • T. Rowe Price Associates's Whitehawk Therapeutics position peaked at $13M in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.